Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Non-Hodgkin Lymphoma through trial conditions or approval indications mapped to it or to one of its descendant entities.
45 drugs · 284 active trials
27 drugs · 479 active trials
56 drugs · 2,316 active trials
Outside the funnel: Phase not stated 1 · Withdrawn 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 18 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Venetoclax | Phase 3 | Phase 3 | 87 | 39 | 15 | 166 | 0 | — | — | Jul 11, 2007 |
| Oxaliplatin | Phase 3 | Phase 3 | 20 | 7 | 14 | 42 | 0 | — | — | 2000-09 |
| Nivolumab | Phase 3 | Phase 3 | 17 | 3 | 3 | 68 | 0 | — | — | Aug 2, 2012 |
| Azacitidine | Phase 3 | Phase 3 | 16 | 11 | 3 | 43 | 0 | — | — | Mar 3, 2006 |
| Carboplatin | Phase 3 | Phase 3 | 14 | 6 | 5 | 45 | 0 | — | — | 2003-08 |
| Pegaspargase | Phase 3 | Phase 3 | 11 | 4 | 13 | 39 | 0 | — | — | Sep 12, 2006 |
| Odronextamab | Phase 3 | Phase 3 | 10 | 7 | 5 | 10 | 0 | — | — | Nov 13, 2019 |
| Duvelisib | Phase 3 | Phase 3 | 9 | 5 | 4 | 29 | 0 | — | — | 2013-05 |
| Copanlisib | Phase 3 | Phase 3 | 8 | 0 | 3 | 32 | 0 | — | — | Nov 19, 2012 |
| Blinatumomab | Phase 3 | Phase 3 | 8 | 4 | 3 | 18 | 0 | — | — | 2004-06 |
| Trametinib | Phase 3 | Phase 3 | 8 | 2 | 1 | 11 | 0 | — | — | Oct 30, 2013 |
| Filgrastim | Phase 3 | Phase 3 | 7 | 3 | 10 | 93 | 0 | — | — | 1995-05 |
| Calaspargase Pegol | Phase 3 | Phase 3 | 7 | 4 | 3 | 8 | 0 | — | — | Jun 19, 2017 |
| Carmustine | Phase 3 | Phase 3 | 6 | 3 | 8 | 49 | 0 | — | — | 1994-01 |
| Sirolimus | Phase 3 | Phase 3 | 6 | 2 | 2 | 36 | 0 | — | — | 2002-07 |
| Lisocabtagene Maraleucel | Phase 3 | Phase 3 | 6 | 3 | 1 | 15 | 0 | — | — | Nov 27, 2017 |
| Leucovorin | Phase 3 | Phase 3 | 5 | 2 | 5 | 23 | 0 | — | — | 2000-02 |
| Tisagenlecleucel | Phase 3 | Phase 3 | 5 | 3 | 2 | 20 | 0 | — | — | Mar 17, 2010 |
| Inotuzumab Ozogamicin | Phase 3 | Phase 3 | 5 | 3 | 3 | 10 | 0 | — | — | 2007-11 |
| Aldesleukin | Phase 3 | Phase 3 | 4 | 4 | 1 | 22 | 0 | — | — | 1995-05 |
| Vemurafenib | Phase 3 | Phase 3 | 4 | 2 | 1 | 8 | 0 | — | — | Apr 12, 2012 |
| Dabrafenib | Phase 3 | Phase 3 | 4 | 1 | 1 | 5 | 0 | — | — | Aug 17, 2015 |
| Nelarabine | Phase 3 | Phase 3 | 3 | 2 | 4 | 14 | 0 | — | — | 1997-06 |
| Ofatumumab | Phase 3 | Phase 3 | 2 | 2 | 5 | 41 | 0 | — | — | 2004-09 |
| Aspirin | Phase 3 | Phase 3 | 2 | 0 | 3 | 8 | 0 | — | — | 2007-01 |
| Chlorambucil | Phase 3 | Phase 3 | 2 | 0 | 5 | 8 | 0 | — | — | 2001-06 |
| Alectinib | Phase 3 | Phase 3 | 2 | 2 | 1 | 2 | 0 | — | — | Dec 18, 2023 |
| Alisertib | Phase 3 | Phase 3 | 1 | 0 | 1 | 11 | 0 | — | — | Jul 11, 2008 |
| Avelumab | Phase 3 | Phase 3 | 1 | 0 | 1 | 9 | 0 | — | — | Dec 16, 2016 |
| Cobimetinib | Phase 3 | Phase 3 | 1 | 1 | 1 | 3 | 0 | — | — | Nov 13, 2017 |
| Teniposide | Phase 3 | Phase 3 | 1 | 1 | 1 | 2 | 0 | — | — | Apr 15, 2013 |
| Sugemalimab | Phase 3 | Phase 3 | 1 | 0 | 1 | 1 | 0 | — | — | 2027-06 |
| Tamoxifen | Phase 3 | Phase 3 | 1 | 0 | 1 | 1 | 0 | — | — | 2024-04 |
| Alemtuzumab | Phase 3 | Phase 3 | 0 | 0 | 1 | 38 | 0 | — | — | 2000-04 |
| Everolimus | Phase 3 | Phase 3 | 0 | 0 | 1 | 21 | 0 | — | — | 2004-04 |
| Mitoxantrone | Phase 3 | Phase 3 | 0 | 0 | 2 | 17 | 0 | — | — | 2001-04 |
| Enzastaurin | Phase 3 | Phase 3 | 0 | 0 | 2 | 8 | 0 | — | — | 2002-06 |
| Tanespimycin | Phase 3 | Phase 3 | 0 | 0 | 2 | 8 | 0 | — | — | 1999-06 |
| Perifosine | Phase 3 | Phase 3 | 0 | 0 | 1 | 7 | 0 | — | — | 2005-12 |
| Bleomycin | Phase 3 | Phase 3 | 0 | 0 | 1 | 4 | 0 | — | — | Jan 8, 2006 |
| Idarubicin | Phase 3 | Phase 3 | 0 | 0 | 3 | 4 | 0 | — | — | 2002-08 |
| Pixantrone | Phase 3 | Phase 3 | 0 | 0 | 1 | 3 | 0 | — | — | 2001-12 |
| Imatinib | Phase 3 | Phase 3 | 0 | 0 | 1 | 2 | 0 | — | — | 2016-08 |
| Masitinib | Phase 3 | Phase 3 | 0 | 0 | 1 | 2 | 0 | — | — | 2005-02 |
| Ibandronic Acid | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | 2006-02 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.